Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Goddard

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|September 1, 1980
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous seriesD E Wilman, P M Goddard
Physical Review Letters|February 5, 2013
Charge radius isotope shift across the N=126 shell gapP M Goddard, P D Stevenson, A Rios
Journal of Pharmaceutical Sciences|January 1, 1980
Antitumor activity of hydrazones and adducts between aromatic aldehydes and p-(3,3-dimethyl-1-triazeno)benzoic acid hydrazideT Giraldi, P M Goddard, C Nisi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary noteP M Goddard, M R Valenti, K R Harrap
Journal of Medicinal Chemistry|June 1, 1977
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivativesT Giraldi, C Nisi, T A Connors, et al.
Biochemical Pharmacology|July 15, 1990
Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicityM G Rowlands, I B Parr, R McCague, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing miceP M Goddard, M Jones, L A Pollard, et al.
Biochemical Pharmacology|February 1, 1976
Tumour inhibitory triazenes: structural requirements for an active metaboliteT A Connors, P M Goddard, K Merai, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1994
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)S E Barrie, G A Potter, P M Goddard, et al.
Journal of Medicinal Chemistry|July 1, 1984
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activityD E Wilman, P J Cox, P M Goddard, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|September 1, 1980
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous seriesD E Wilman, P M Goddard
Physical Review Letters|February 5, 2013
Charge radius isotope shift across the N=126 shell gapP M Goddard, P D Stevenson, A Rios
Journal of Pharmaceutical Sciences|January 1, 1980
Antitumor activity of hydrazones and adducts between aromatic aldehydes and p-(3,3-dimethyl-1-triazeno)benzoic acid hydrazideT Giraldi, P M Goddard, C Nisi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary noteP M Goddard, M R Valenti, K R Harrap
Journal of Medicinal Chemistry|June 1, 1977
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivativesT Giraldi, C Nisi, T A Connors, et al.
Biochemical Pharmacology|July 15, 1990
Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicityM G Rowlands, I B Parr, R McCague, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing miceP M Goddard, M Jones, L A Pollard, et al.
Biochemical Pharmacology|February 1, 1976
Tumour inhibitory triazenes: structural requirements for an active metaboliteT A Connors, P M Goddard, K Merai, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1994
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)S E Barrie, G A Potter, P M Goddard, et al.
Journal of Medicinal Chemistry|July 1, 1984
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activityD E Wilman, P J Cox, P M Goddard, et al.
Pageof 3